SCHEMBL854096

SCHEMBL854096

N#CCNC(=O)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CTSS P25774 13/20 0.68
CTSL P07711 11/20 0.68
CTSB P07858 7/20 0.68
CTSK P43235 3/20 0.68
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1606573 0.85 LMNA (0.61) CTSSCTSLCTSBCTSKLMNA
SCHEMBL2391033 0.84 LMNA (0.65) CTSSCTSLCTSBCTSKLMNA
SCHEMBL5532541 0.84 CTSS (0.62) CTSSCTSLCTSBCTSKLMNA
SCHEMBL3211861 0.83 LMNA (0.59) CTSSCTSLCTSBCTSKLMNA
SCHEMBL6185607 0.83 CTSS (0.60) CTSSCTSLCTSBCTSKLMNA
SCHEMBL6183076 0.83 HTT (0.60) CTSSCTSLCTSBCTSKLMNA
SCHEMBL6048184 0.83 CTSS (0.61) CTSSCTSLCTSBCTSKLMNA
SCHEMBL5532252 0.82 CTSS (0.60) CTSSCTSLCTSBCTSKLMNA
Benzyl Phenethylcarbamate SCHEMBL27338403 0.81 LMNA (0.61) CTSSCTSLCTSBCTSKLMNA
SCHEMBL12176970 0.81 HTT (0.67) CTSSCTSLCTSBCTSKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934561-B1 IMPROVED TIME/TEMPERATURE INDICATORS SUN CHEMICAL CORP (US) 2018-11-07 EP claimed
US-20080269050-A1 Time/Temperature Indicators SUN CHEMICAL CORPORATION (US) 2008-10-30 US claimed
EP-1934561-A1 IMPROVED TIME/TEMPERATURE INDICATORS Sun Chemical Corporation (US) 2008-06-25 EP claimed
WO-2007035365-A1 IMPROVED TIME/TEMPERATURE INDICATORS SUN CHEMICAL CORPORATION (US) 2007-03-29 WO claimed
WO-2006091464-A1 IMPROVED TIME/ TEMPERATURE INDICATORS SUN CHEMICAL CORPORATION (US) 2006-08-31 WO claimed
WO-2006091465-A1 TIME/TEMPERATURE INDICATORS, THEIR PREPARATION AND USE SUN CHEMICAL CORPORATION (US) 2006-08-31 WO claimed
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 US disclosed
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines H. LUNDBECK A/S (DK) 2023-12-26 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines H. LUNDBECK A/S (DK) 2023-04-25 US disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed
CN-110099901-B Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors H.隆德贝克有限公司 2023-01-03 CN disclosed
WO-1997045403-A1 ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1997-12-04 WO disclosed
US-5629285-A Inhibitors of TNF-α secretion IMMUNEX CORPORATION (US) 1997-05-13 US disclosed
EP-0715619-A4 INHIBITORS OF TNF-ALPHA SECRETION IMMUNEX CORP (US) 1997-03-19 EP disclosed
US-5594106-A Inhibitors of TNF-α secretion IMMUNEX CORPORATION (US) 1997-01-14 US disclosed
EP-0715619-A1 INHIBITORS OF TNF-ALPHA SECRETION IMMUNEX CORPORATION (US) 1996-06-12 EP disclosed
WO-1995006031-A1 INHIBITORS OF TNF-ALPHA SECRETION IMMUNEX CORPORATION (US) 1995-03-02 WO disclosed
EP-0201999-A1 Substituted 2-cyano-2-oximino-acetamides, processes for their production and their use as fungicides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CTSS 3253/4885CTSL 2966/4885CTSB 3022/4885
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines PDE3B, PDE1B, PDE12 CTSS 1996/4885CTSL 3166/4885CTSB 896/4885
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines PDE1B, PDE3B, PDE1A CTSS 1985/4885CTSL 2791/4885CTSB 1206/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS CTSS 3253/4885CTSL 2966/4885CTSB 3022/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CTSS 3253/4885CTSL 2966/4885CTSB 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.